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Background: The CpG island methylator phenotype (CIMP) of clear cell renal cell carcinomas (ccRCCs) is characterized
by accumulation of DNA methylation at CpG islands and poorer patient outcome. The aim of this study was to
establish criteria for prognostication of patients with ccRCCs using the ccRCC-specific CIMP marker genes.
Methods: DNA methylation levels at 299 CpG sites in the 14 CIMP marker genes were evaluated quantitatively in
tissue specimens of 88 CIMP-negative and 14 CIMP-positive ccRCCs in a learning cohort using the MassARRAY system.
An additional 100 ccRCCs were also analyzed as a validation cohort.
Results: Receiver operating characteristic curve analysis showed that area under the curve values for the 23 CpG units
including the 32 CpG sites in the 7 CIMP-marker genes, i.e. FAM150A, ZNF540, ZNF671, ZNF154, PRAC, TRH and SLC13A5,
for discrimination of CIMP-positive from CIMP-negative ccRCCs were larger than 0.95. Criteria combining the 23 CpG
units discriminated CIMP-positive from CIMP-negative ccRCCs with 100% sensitivity and specificity in the learning
cohort. Cancer-free and overall survival rates of patients with CIMP-positive ccRCCs diagnosed using the criteria
combining the 23 CpG units in a validation cohort were significantly lower than those of patients with CIMP-negative
ccRCCs (P = 1.41 × 10−5 and 2.43 × 10−13, respectively). Patients with CIMP-positive ccRCCs in the validation cohort had
a higher likelihood of disease-related death (hazard ratio, 75.8; 95% confidence interval, 7.81 to 735; P = 1.89 × 10−4)
than those with CIMP-negative ccRCCs.
Conclusions: The established criteria are able to reproducibly diagnose CIMP-positive ccRCCs and may be useful for
personalized medicine for patients with ccRCCs.
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renal cell carcinoma (ccRCC)Background
Clear cell renal cell carcinoma (ccRCC) is the most com-
mon histological subtype of adult kidney cancer [1]. In
general, ccRCCs at an early stage are curable by nephrec-
tomy. However, some ccRCCs relapse and metastasize to
distant organs, even if the resection has been considered
complete [2]. Even though novel targeting agents have
been developed for treatment of ccRCC, unless relapsed* Correspondence: earai@ncc.go.jp
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unless otherwise stated.or metastasized tumors are diagnosed early by close
follow-up, the effectiveness of any therapy is restricted
[3]. Therefore, reliable prognostic criteria need to be
established.
Not only genetic, but also epigenetic events appear to
accumulate during carcinogenesis, and DNA methyla-
tion alterations are one of the most consistent epigenetic
changes in human cancers [4-6]. We and other groups
have revealed that DNA methylation alterations par-
ticipate in renal carcinogenesis and are significantly cor-
related with the clinicopathological diversity of ccRCCs
[7-11]. In addition, a distinct cancer phenotype known. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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acterized by accumulation of DNA methylation at CpG
islands, has been defined in well-studied cancers [12,13]
such as those of the colorectum [14] and stomach [15],
and shown to be significantly correlated with clinico-
pathological parameters. Although the relevance of the
CIMP-positive phenotype in the context of ccRCCs has
not yet been clearly defined [16], our group very recently
identified CIMP-positive ccRCCs based on genome-wide
DNA methylation analysis [7]. We also identified 17
genes, i.e. FAM150A, GRM6, ZNF540, ZFP42, ZNF154,
RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC,
WNT3A, TRH, FAM78A, ZNF671, SLC13A5 and NKX6-2,
which are hallmarks of CIMP in ccRCCs [7], using single
CpG-resolution Infinium assay [17]. The CIMP-positive
ccRCCs in our cohort were clinicopathologically aggres-
sive and associated with poorer patient outcome [7], indi-
cating that CIMP in ccRCCs might be applicable as a
prognostic indicator.
However, in our previous study, CIMP-positive ccRCCs
were identified using hierarchical clustering analysis based
on DNA methylation profiles in the examined cohort [7].
The DNA methylation status of entire promoter CpG
islands, other than Infinium probe sites, in the CIMP
marker genes has not been evaluated quantitatively.
Therefore, to establish criteria for CIMP diagnosis that
would be applicable to individual patients, CpG sites ha-
ving the largest diagnostic impact should be identified in
the entire promoter CpG islands of the CIMP marker
genes based on quantification of DNA methylation levels.
Moreover, appropriate cutoff values of DNA methylation
levels need to be established for the identified CpG sites in
order to discriminate CIMP-positive from CIMP-negative
ccRCCs.
In the present study, we quantitatively evaluated DNA
methylation levels at 299 CpG sites throughout the pro-
moter CpG islands of the ccRCC-specific CIMP marker
genes in 88 CIMP-negative ccRCCs and 14 CIMP-positive
ccRCCs using the MassARRAY system. We then validated
the prognostic impact of the established criteria for CIMP
diagnosis in a validation cohort of 100 additional ccRCCs.
Methods
Patients and tissue samples
As a learning cohort, 102 samples of cancerous tissue
obtained from specimens surgically resected from 102 pa-
tients with primary ccRCCs were subjected to the present
analysis. These patients did not receive preoperative treat-
ment and underwent nephrectomy at the National Cancer
Center Hospital, Tokyo, Japan. There were 71 men and
31 women with a mean (± standard deviation) age of
62.9 ± 10.4 years (range, 36 to 85 years). Histological diag-
nosis was made in accordance with the World Health
Organization classification [18].In our previous study, unsupervised hierarchical clus-
tering based on genome-wide DNA methylation analysis
using single CpG-resolution Infinium assay divided the
102 ccRCCs in the learning cohort into 88 CIMP-negative
ccRCCs and 14 CIMP-positive ccRCCs [7]. In the same
study, we showed that the CIMP-positive ccRCCs were
clinicopathologically more aggressive and associated with
a poorer patient outcome than CIMP-negative ccRCCs [7]:
the clinicopathological characteristics [19,20] of CIMP-
negative and CIMP-positive ccRCCs in the learning cohort
are summarized in Additional file 1: Table S1.
As a validation cohort, 100 samples of cancerous tissue
were obtained from specimens surgically resected from
100 patients with primary ccRCCs. These patients also did
not receive preoperative treatment and underwent neph-
rectomy at the National Cancer Center Hospital, Tokyo,
Japan. The patients comprised 68 men and 32 women
with a mean (± standard deviation) age of 62.5 ± 11.4 years
(range, 33 to 87 years). The clinicopathological charac-
teristics [19,20] of ccRCCs in the validation cohort are
summarized in Additional file 2: Table S2.
Tissue specimens were taken and frozen immediately
after surgical removal and have been stored in liquid
nitrogen until DNA extraction. ccRCCs are hypervascu-
lar tumors with an increased opportunity for infiltration
of non-cancerous cells such as lymphocytes [21]: the
microscopically examined tumor cell contents (%) of all
ccRCC tissue specimens in the learning and validation
cohorts are shown in Additional file 3: Table S3. Tissue
specimens were provided by the National Cancer Center
Biobank, Tokyo, Japan. This study was approved by the
Ethics Committee of the National Cancer Center, Tokyo,
Japan, and was performed in accordance with the
Declaration of Helsinki. All the patients provided written
informed consent prior to inclusion in the study.
DNA extraction and bisulfite modification
High-molecular-weight DNA was extracted from fresh-
frozen tissue samples using phenol-chloroform followed
by dialysis [22]. One microgram of genomic DNA was
subjected to bisulfite treatment using an EpiTect Bisulfite
Kit (QIAGEN GmbH, Hilden, Germany), in accordance
with the manufacturer’s protocol. This process converts
non-methylated cytosine to uracil, while methylated cyto-
sine remains unchanged [23].
Quantitative DNA methylation analysis with the
MassARRAY system
DNA methylation levels at individual CpG sites were
evaluated quantitatively using the MassARRAY platform
(Sequenom, San Diego, CA). This method utilizes base-
specific cleavage and matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF
MS) [24]. Specific PCR primers for bisulfite-converted
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age (www.epidesigner.com, Sequenom), encompassing all
promoter CpG islands of the previously identified ccRCC-
specific CIMP marker genes [7]. The sequences of the 16
primer sets are given in Additional file 4: Table S4. A
T7-promoter tag (5′-CAGTAATACGACTCACTATAGG
GAGAAGGCT-3′) was added to each reverse primer for
in vitro transcription, and a 10-mer tag (5′-AGGAAGA
GAG-3′) was added to each forward primer to balance
the PCR.
To overcome PCR bias in DNA methylation analysis,
we optimized the annealing temperature and type of DNA
polymerase: 0%, 50% and 100% methylated control DNA
(Epitect methylated human control DNA; QIAGEN) was
used as template to test the linearity of the protocol. Using
HotStar Taq DNA polymerase (QIAGEN) or TaKaRa Taq
HS DNA polymerase (Takara Bio, Shiga, Japan), the
annealing temperature for each of the 16 primer sets was
set to give a correlation coefficient (R2) of more than 0.9
and to make the slope of the standard curve close to 1
(Additional file 5: Figure S1 and Additional file 4:
Table S4). The PCR products were separated electrophor-
etically on 2% agarose gel and stained with ethidium
bromide to confirm that specific products of the appropri-
ate size and no non-specific products were obtained upon
amplification.
Then, the PCR products were used as a template for
in vitro transcription and the RNase A-mediated cleavage
reaction using an EpiTYPER Reagent Kit (Sequenom). The
fragmented samples were dispensed onto a SpectroCHIP
array, and then detected on a MassARRAY analyzer com-
pact MALDI-TOF MS instrument. The data were visua-
lized using EpiTYPER Analyzer software v1.0 (Sequenom).
The DNA methylation level (%) at each CpG site was de-
termined by comparing the signal intensities of methylated
and non-methylated templates. A cluster of consecutive
CpG sites, each giving one measured value by the
MassARRAY system, is defined as a “CpG unit” in the
manufacturer’s protocol. The DNA methylation levels at
the 299 examined CpG sites in the CIMP marker genes
were then expressed as data for the 193 CpG units. Experi-
ments were performed in triplicate for each sample-CpG
unit, and the mean value for the three experiments was
used as the DNA methylation level.
Statistics
Differences in DNA methylation levels at individual CpG
units between CIMP-positive ccRCCs and CIMP-negative
ccRCCs were analyzed using Mann–Whitney U test. The
CpG units having the largest diagnostic impact were iden-
tified by receiver operating characteristic (ROC) curve
analysis [25]: For 23 CpG units showing area under the
curve (AUC) values larger than 0.95, appropriate cutoff
values were determined in order to discriminate CIMP-positive from CIMP-negative ccRCCs [26]. For discrimi-
nating CIMP-positive from CIMP-negative ccRCCs, the
Youden index [26] was used as a cutoff value for each
CpG unit. Survival curves for patients with ccRCCs were
analyzed by the Kaplan-Meier method and the log-rank
test. Correlations between DNA methylation levels and re-
currence and disease-related death were analyzed using
the Cox proportional hazards model. All statistical ana-
lyses were performed using SPSS statistics version 20
(IBM Corp., Armonk, NY). Differences at P values of less
than 0.05 were considered statistically significant.
Results
DNA methylation status of CIMP marker genes in
CIMP-negative and CIMP-positive ccRCCs
Previously, we had identified 17 ccRCC-specific CIMP
marker genes based on genome-wide DNA methylation
analysis using the Infinium HumanMethylation27K
BeadChip [7]. Six exact Infinium probe CpG sites in
ccRCC-specific CIMP marker genes (Probe ID: cg06274159
for the ZFP42 gene, cg03975694 for the ZNF540 gene,
cg08668790 for the ZNF154 gene, cg01009664 for the
TRH gene, cg22040627 for the SLC13A5 gene, and
cg19246110 for the ZNF671 gene) were examined using
the MassArray system in the learning cohort (Additional
file 6; Figure S2). Significant correlations between DNA
methylation levels determined by our previous Infinium
assay [7] and those determined by the present MassArray
analysis were statistically confirmed (P = 1.25 × 10−35,
P = 1.98 × 10−32, P = 1.31 × 10−41, P = 5.30 × 10−34,
P = 7.91 × 10−22 and P = 7.61 × 10−44, respectively).
In the present study, our primary intention was to
evaluate quantitatively the DNA methylation status of not
only the Infinium probe sites but also the entire promoter
CpG islands in the ccRCC-specific CIMP marker genes
using the MassARRAY system [24]. Since the promoter
regions of the CIMP marker genes, KCNQ1, FAM78A and
NKX6-2, have a very high GC content, for these three
genes we were unable to set optimized PCR conditions.
Then, the DNA methylation status of 193 CpG units in-
cluding 299 CpG sites in the remaining 14 ccRCC-specific
CIMP marker genes, i.e. FAM150A, GRM6, ZNF540,
ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2,
PRAC, WNT3A, TRH, ZNF671 and SLC13A5, was eva-
luated quantitatively using the MassARRAY system. The
average DNA methylation levels of 38 CpG units inclu-
ding 68 CpG sites located within the 1347 bp 5′-region
of the representative CIMP marker gene, SLC13A5,
in CIMP-negative (n = 88) and CIMP-positive (n = 14)
ccRCCs in the learning cohort are shown in Figure 1A.
Similarly, the average DNA methylation levels of 21 CpG
units including 29 CpG sites located within the 428 bp
5′-region of another representative CIMP marker gene,
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Figure 1 Average DNA methylation levels at promoter CpG islands in the SLC13A5 (A) and ZNF671 (B) genes in CIMP-negative (n = 88)
and CIMP-positive (n = 14) ccRCCs in the learning cohort. DNA methylation levels of each CpG unit were evaluated quantitatively using the
MassARRAY system. A. Average DNA methylation levels of all examined 38 CpG units including 68 CpG sites located within 1347 bp 5′ region of
the SLC13A5 gene in CIMP-positive ccRCCs (red line) were significantly higher than those in CIMP-negative ccRCCs (blue line). B. Average DNA
methylation levels of all examined 21 CpG units including 29 CpG sites located within the 428 bp 5′ region of the ZNF671 gene in CIMP-positive
ccRCCs (red line) were significantly higher than those in CIMP-negative ccRCCs (blue line). *P < 0.05 and **P < 0.01. Exact P values for each CpG
unit of the SLC13A5 and ZNF671 genes are summarized in Additional file 7: Table S5. Error bar: standard error.
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DNA methylation levels of all the CpG units examined
(59 in total) in the SLC13A5 and ZNF671 genes in the
CIMP-positive ccRCCs were significantly higher than
those in CIMP-negative ccRCCs (the P values for each
CpG unit are shown in Additional file 7: Table S5). Simi-
larly, the average DNA methylation levels of 130 CpG
units including 195 CpG sites, out of the 134 CpG units
examined including 202 CpG sites in the remaining 12
CIMP marker genes, in the CIMP-positive ccRCCs were
significantly higher than those in CIMP-negative ccRCCs
(Additional file 7: Table S5). These data indicated that
almost the entire promoter CpG islands in all the CIMP
marker genes examined were methylated in CIMP-
positive ccRCCs.Establishment of criteria for discriminating CIMP-positive
from CIMP-negative ccRCCs in the learning cohort
Since quantitative DNA methylation analysis using the
MassARRAY system revealed that many CpG sites showed
significant differences in DNA methylation levels between
CIMP-negative and CIMP-positive ccRCCs among all the
promoter CpG islands of CIMP marker genes (Figure 1
and Additional file 7: Table S5), we attempted to identify
CpG sites having the largest diagnostic impact, and to
establish criteria for discriminating CIMP-positive from
CIMP-negative ccRCCs. ROC curves were constructed for
all 193 CpG units examined, including 299 CpG sites in
the 14 CIMP marker genes examined, and the cor-
responding AUC values [25] were calculated. Eighty-six
CpG units, including 135 CpG sites, showed AUC values
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86, the top 23 CpG units including 32 CpG sites showing
AUC values larger than 0.95 were used to establish the cri-
teria for discriminating CIMP-positive from CIMP-negative
ccRCCs (Table 1). For discriminating CIMP-positive from
CIMP-negative ccRCCs, the Youden index [26] was used as
a cutoff value for each CpG unit (Table 1).
Figure 2A shows scattergrams of the DNA methylation
levels of representative CpG units in CIMP-negative and
CIMP-positive ccRCCs in the learning cohort along with
cutoff values listed in Table 1. The sensitivity and spe-
cificity of such discrimination using the cutoff values de-
rived for each CpG unit are shown in Figure 2A and
Table 1. A histogram showing the number of CpG units
showing DNA methylation levels higher than the cutoff
values listed in Table 1 in the learning cohort is shown
in Figure 2B. All 14 ccRCCs showing DNA methylationTable 1 The 23 CpG units showing area under the curve (AUC
characteristic curve analysis for discrimination of CpG island
carcinomas (ccRCCs) from CIMP-negative ccRCCs in the learni
ID of
CpG unit1
Gene symbol Chromo-some Position of CpG site2
81 TRH 3 129693406, 129693412
85 TRH 3 129693518, 129693521, 129
89 TRH 3 129693586
94 TRH 3 129693635
8 FAM150A 8 53478477
11 FAM150A 8 53478511
78 PRAC 17 46799755
102 SLC13A5 17 6616733
105 SLC13A5 17 6616812
106 SLC13A5 17 6616826, 6616828
107 SLC13A5 17 6616851, 6616854, 6616857
110 SLC13A5 17 6616927, 6616929
30 ZNF540 19 38042496
32 ZNF540 19 38042518
33 ZNF540 19 38042530, 38042532
43 ZNF154 19 58220567
44 ZNF154 19 58220627
45 ZNF154 19 58220657, 58220662
149 ZNF671 19 58238780
158 ZNF671 19 58238928
160 ZNF671 19 58238954
161 ZNF671 19 58238987
163 ZNF671 19 58239012
1ID of CpG unit is defined in Additional file 4: Table S4.
2National Center for Biotechnology Information (NCBI) Database (Genome Build 37)
3The Youden index was used as a cutoff value for discriminating CIMP-positive ccRC
tissue shows a DNA methylation level equal to or higher than the cutoff value, the
DNA methylation level lower than the cutoff value, the ccRCC is considered to be C
4Sensitivity and specificity for discrimination of CIMP-positive ccRCCs in the learninglevels higher than the cutoff values listed in Table 1 at 16
or more CpG units based on the present MassARRAY
analysis (red bars in Figure 2B) were CIMP-positive
ccRCCs identified by our previous hierarchical clustering
based on the Infinium assay. All 88 ccRCCs showing
DNA methylation levels higher than the cutoff values
listed in Table 1 at less than 16 CpG units based on the
present MassARRAY analysis (blue bars in Figure 2B)
were CIMP-negative ccRCCs identified by our previous
hierarchical clustering based on the Infinium assay.
Based on Figure 2B, we established the following cri-
teria: when ccRCC tissue shows DNA methylation levels
higher than the cutoff values listed in Table 1 at 16 or
more CpG units (green line in Figure 2B), it is judged to
be CIMP-positive. When ccRCC tissue shows DNA
methylation levels higher than the cutoff values listed in
Table 1 at less than 16 CpG units, it is judged to be) values larger than 0.95 in receiver operating
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Figure 2 (See legend on next page.)
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Figure 2 The criteria for CIMP diagnosis discriminating CIMP-positive from CIMP-negative ccRCCs based on the MassARRAY system.
A. Scattergrams of DNA methylation levels of representative CpG units in the learning cohort. Using each CpG unit and its cutoff value (CV)
described in Table 1, CIMP-positive ccRCCs were discriminated from CIMP-negative ccRCCs with sufficient sensitivity and specificity. B. Histogram
showing the number of CpG units with DNA methylation levels higher than the cutoff values listed in Table 1 in the learning cohort. All 14
ccRCCs (red columns) showing DNA methylation levels higher than the cutoff values at 16 or more CpG units were CIMP-positive ccRCCs, and all
88 ccRCCs (blue columns) showing DNA methylation levels higher than the cutoff values at less than 16 CpG units were CIMP-negative ccRCCs.
On the basis of this histogram, we established the following criteria: When the cancerous tissue showed DNA methylation levels higher than the
cutoff values at 16 (green bar) or more CpG units, it was judged to be CIMP-positive. The number of CpG units showing higher DNA methylation
levels than the cutoff values in CIMP-positive ccRCCs (20.79 ± 0.69) was higher than that of CIMP-negative ccRCCs (2.09 ± 0.32, P = 8.75 × 10−10).
C. Histogram showing the number of CpG units with DNA methylation levels higher than the cutoff values listed in Table 1 in the additional 100
ccRCCs comprising the validation cohort. Using the criteria established on the basis of panel B, 5 ccRCCs (black bars) were diagnosed as CIMP-positive
ccRCCs, whereas 95 ccRCCs (gray bars) were diagnosed as CIMP-negative ccRCCs. The number of CpG units showing higher DNA methylation levels
than the cutoff values in ccRCCs diagnosed as CIMP-positive (18.00 ± 0.84) was higher than that of ccRCCs diagnosed as CIMP-negative (2.73 ± 0.30,
P = 1.41 × 10−4).
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ccRCCs in the learning cohort were discriminated
from CIMP-negative ccRCCs with 100% sensitivity and
specificity.
Prognostic impact of CIMP diagnosis in the validation
cohort
It has previously been revealed that patients with CIMP-
positive ccRCCs show a poorer outcome [7]. Therefore,
we attempted to validate the prognostic impact of CIMP
diagnosis using criteria based on the cutoff values listed
in Table 1. Using the additional 100 ccRCCs in the va-
lidation cohort, DNA methylation levels at the 23 CpG
units including the 32 CpG sites in Table 1 were evalu-
ated quantitatively using the MassARRAY system. The
DNA methylation statuses of the 100 ccRCCs in the
validation cohort were used to construct a histogram
showing the number of CpG units with DNA methyla-
tion levels higher than the cutoff values listed in Table 1Figure 3 Kaplan–Meier survival curves of patients with CIMP-positive
P = 1.41 × 10−5) and overall (Panel B, P = 2.43 × 10−13) survival rates of patie
cutoff values listed in Table 1 at 16 or more CpG units (diagnosed as CIMP
ccRCCs showing DNA methylation levels higher than the cutoff values liste
ccRCCs). Patients who underwent curative resection were included in pane
established in the present study was clearly confirmed in the validation co(Figure 2C). The distribution of DNA methylation status
at the 23 CpG units of the ccRCCs in the validation
cohort (Figure 2C) was similar to that in the learning
cohort (Figure 2B). Based on the criteria for CIMP diag-
nosis established using the learning cohort, 5 ccRCCs
showing DNA methylation levels higher than the cutoff
values listed in Table 1 at 16 or more CpG units were
diagnosed as CIMP-positive, whereas 95 ccRCCs sho-
wing such higher DNA methylation levels at less than 16
CpG units were diagnosed as CIMP-negative.
Survival curves of the 100 patients belonging to the
validation cohort were calculated by the Kaplan-Meier
method (Figure 3). The period covered ranged from 27 to
5,031 days (mean: 1,860 days). Cancer-free (Figure 3A) and
overall (Figure 3B) survival rates of patients with CIMP-
positive ccRCCs diagnosed using the criteria based on the
cutoff values listed in Table 1 were significantly lower than
those of patients with CIMP-negative ccRCCs (P = 1.41 ×
10−5 and 2.43 × 10−13, respectively, log-rank test).and negative ccRCCs in the validation cohort. Cancer-free (Panel A,
nts with ccRCCs showing DNA methylation levels higher than the
-positive ccRCCs) were significantly lower than those of patients with
d in Table 1 at less than 16 CpG units (diagnosed as CIMP-negative
l A. The prognostic significance of the criteria for CIMP-diagnosis
hort.
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validation cohort, one tumor was grade 2, two were
grade 3, and two were grade 4 (Figure 2C); four were
stage III and one was stage IV. Even after adjusting the
grades, the cancer-free (P = 1.01 × 10−3) and overall
(P = 7.04 × 10−4) survival rates of patients with CIMP-
positive high-grade (grades 3 and 4) ccRCCs were
significantly lower than those of patients with CIMP-
negative high-grade (grades 3 and 4) ccRCCs (log-rank
test, Additional file 9: Figure S3). The cancer-free
(P = 7.76 × 10−4) and overall (P = 5.48 × 10−5) survival
rates of patients with CIMP-positive high-stage (stages
III and IV) ccRCCs were significantly lower than those
of patients with CIMP-negative high-stage (stages III
and IV) ccRCCs in the validation cohort (log-rank test,
Additional file 9: Figure S3).
When compared with CIMP-negative ccRCCs, the
CIMP-positive ccRCCs in the validation cohort had
a significantly higher likelihood of recurrence (hazard
ratio, 10.6; 95 percent confidence interval, 2.81 to 40.2;
P = 5.03 × 10−4), and of disease-related death (hazard
ratio, 75.8; 95 percent confidence interval, 7.81 to 735;
P = 1.89 × 10−4) (Cox proportional hazards model). These
data indicated that the validation cohort clearly demon-
strated the prognostic significance of the criteria for CIMP
diagnosis established in the present study.
Discussion
Since the effectiveness of any therapy for relapsed or
metastasized ccRCC is restricted unless it is diagnosed
early by close follow-up after nephrectomy [3], sig-
nificant prognostic criteria need to be established. Unlike
alterations of mRNA and protein expression, which can
be easily affected by the microenvironment of cancer
cells, DNA methylation alterations are stably preserved
on DNA double strands by covalent bonds [4,5]. There-
fore, DNA methylation levels at appropriate marker
CpG sites would appear to be optimal prognostic indica-
tors if evaluated quantitatively [27].
The present learning cohort comprised 88 CIMP-
negative ccRCCs and 14 CIMP-positive ccRCCs: CIMP
in the learning cohort was identified using hierarchical
clustering based on single CpG-resolution Infinium
assay in our previous study [7], which had revealed that
CIMP-positive ccRCCs in the learning cohort were clini-
copathologically aggressive tumors with a larger dia-
meter, more frequent vascular involvement, infiltrating
growth, and renal pelvis invasion, as well as having
higher histological grades and pathological TNM stages
than CIMP-negative ccRCCs [7] (Additional file 1: Table
S1). During the follow-up period after nephrectomy, the
cancer-free and overall survival rates of patients with
CIMP-positive ccRCCs in the learning cohort were sig-
nificantly lower than those of patients with CIMP-negative ccRCCs in our previous study [7], indicating
that CIMP in ccRCCs might be applicable as a prog-
nostic indicator.
We previously identified ccRCC-specific CIMP marker
genes whose DNA methylation levels differed markedly
between CIMP-negative and CIMP-positive ccRCCs
based on the Infinium assay [7]. Since hierarchical clus-
tering is not applicable to clinical use, in the present
study we attempted to establish criteria for CIMP diag-
nosis that would be applicable to patients admitted to
hospitals on an individual basis. The DNA methylation
status of all promoter CpG islands, even CpG sites other
than the Infinium probe sites, in the CIMP marker genes
was evaluated quantitatively using the MassARRAY sys-
tem, which is known to be suitable for quantification of
multiple CpG sites [24]. Moreover, we carefully opti-
mized the experimental conditions for MassARRAY ana-
lysis in order to avoid any PCR bias (Additional file 4:
Table S4).
It was revealed that the entire promoter CpG islands in
all the CIMP marker genes examined, i.e. FAM150A,
GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1,
KHDRBS2, ASCL2, PRAC, WNT3A, TRH, ZNF671 and
SLC13A5, were methylated in CIMP-positive ccRCCs with-
out exception (Figure 1 and Additional file 7: Table S5).
Within such promoter CpG islands, there were many
CpG sites where DNA methylation levels were useful for
discrimination of CIMP-positive ccRCCs in the learning
cohort from CIMP-negative ccRCCs (Additional file 8:
Table S6). We identified the top 23 CpG units whose
AUC values were larger than 0.95 in ROC analysis, and
the Youden index was used as a cutoff value for such dis-
crimination in each CpG unit (Table 1). The sensitivity
and specificity of each of the 23 CpG units was sufficient
for such discrimination (Table 1 and Figure 2A). More-
over, combination of the 23 CpG units generated criteria
with 100% sensitivity and specificity for discrimination
of CIMP-positive ccRCCs in the learning cohort from
CIMP-negative ccRCCs (Figure 2B).
As a validation cohort, an additional 100 ccRCCs that
had not been previously subjected to Infinium assay or
hierarchical clustering were analyzed. The distribution of
DNA methylation levels at the 23 CpG units in the vali-
dation cohort (Figure 2C) was quite similar to that in the
learning cohort (Figure 2B), indicating that distinct DNA
methylation profiles of the 23 CpG units are reproducible
in ccRCCs. In the validation cohort, 5 ccRCCs were diag-
nosed as CIMP-positive based on the criteria established
in the present MassARRAY analysis (Table 1). CIMP-
positive ccRCCs diagnosed in the validation cohort had
significantly lower cancer-free and overall survival rates
than those of CIMP-negative ccRCCs (Figure 3). Even after
adjusting the grades and stages, the cancer-free and overall
survival rates of patients with high-grade (grade 3/4) and
Tian et al. BMC Cancer 2014, 14:772 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/772high-stage (stage III/IV) CIMP-positive ccRCCs were sig-
nificantly lower than those of patents with high-grade
(grade 3/4) and high-stage (stage III/IV) CIMP-negative
ccRCCs (Additional file 9: Figure S3). Moreover, CIMP-
positive ccRCCs had a higher likelihood of both recur-
rence and disease-related death (hazard ratios 10.6 and
75.8, respectively). These data indicated that CIMP of
ccRCCs can be reproducibly diagnosed using the criteria
established in the present study, and that CIMP diagnosis
is useful for prognostication of patients with ccRCCs.
Reproducible diagnosis of CIMP using the criteria
established in the present study makes it possible to ex-
plore the molecular background of CIMP-positive renal
carcinogenesis. Since CIMP-positive ccRCCs show clini-
copathological aggressiveness and poorer outcome [7],
the molecular pathways participating in CIMP-positive
renal carcinogenesis should be clarified and the thera-
peutic targets of CIMP-positive ccRCCs need to be iden-
tified. Even though we [28] and another group [29,21]
reported the results of multilayer omics analyses in
ccRCCs, such reports did not focus on CIMP. Therefore
we are now performing multilayer omics (i.e. genome
(whole-exome), transcriptome and proteome) analyses of
tissue specimens from CIMP-negative and -positive
ccRCCs. Frequently affected molecular pathways that
might potentially become therapeutic targets are now
being identified in more aggressive CIMP-positive ccRCCs
(unpublished data).
The criteria for CIMP diagnosis established in the
present study may be useful for not only prognostication
but also companion diagnostics for personalized medi-
cine [30]. If our CIMP diagnosis reveals CIMP-negativity
in samples of tumor tissue obtained by nephrectomy,
the risk of recurrence and metastasis would be consi-
dered low, and such patients would not require adjuvant
therapy. On the other hand, if our CIMP diagnosis re-
veals CIMP-positivity, then the risk of recurrence and
metastasis would be considered high. Therefore, close
follow-up and frequent imaging diagnosis are recom-
mended for early diagnosis of recurrence. In addition,
inhibitors for frequently affected molecular pathways
identified by multilayer omics analysis in CIMP-positive
ccRCCs might be effective after recurrence. If further
preclinical examinations support the effectiveness of ad-
juvant therapy using inhibitors for frequently affected
molecular pathways in CIMP-positive ccRCCs, such ad-
juvant therapy may be recommended immediately after
nephrectomy in patients with CIMP-positive ccRCCs.
Conclusions
CIMP of ccRCCs is characterized by accumulation of
DNA methylation at CpG islands and poorer patient out-
come. Based on quantification of DNA methylation levels
of the ccRCC-specific CIMP marker genes, the criteria forCIMP diagnosis have been established. CIMP of ccRCCs
can be reproducibly diagnosed using the criteria estab-
lished in the present study. The prognostic significance of
the criteria has been clearly validated in the validation co-
hort. Frequently affected molecular pathways that might
potentially become therapeutic targets are now being
identified using multilayer omics analyses in more aggres-
sive CIMP-positive ccRCCs. The criteria for CIMP diag-
nosis may be useful for not only prognostication but also
companion diagnostics for personalized medicine.
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Additional file 1: Table S1. Correlation between CpG island methylator
phenotype (CIMP) and clinicopathological parameters of clear cell renal
cell carcinomas (ccRCCs) in the learning cohort.
Additional file 2: Table S2. Clinicopathological characteristics of clear
cell renal cell carcinomas (ccRCCs) in the validation cohort.
Additional file 3: Table S3. Microscopically examined tumor cell
content (%) of specimens of clear cell renal cell carcinoma tissue from
the learning and validation cohorts.
Additional file 4: Table S4. Primer sequences and optimal PCR
conditions for MassARRAY.
Additional file 5: Figure S1. Standard curves for optimization of PCR
conditions for the MassARRAY system on representative CpG units. To
test the linearity of the protocol, 0%, 50% and 100% methylated control
DNA was used as a template. Experiments were performed in triplicate
for each sample-CpG unit, and the mean value for the three experiments
was used as the DNA methylation level. Error bar: standard deviation.
Optimized PCR conditions (annealing temperature and type of DNA
polymerases) are summarized in Additional file 4: Table S4.
Additional file 6: Figure S2. Scattergrams of DNA methylation levels
determined by Infinium assay and those determined by MassArray
analysis. aProbe ID for the Infinium HumanMethylation27 Bead Array. Six
exact Infinium probe CpG sites (cg06274159 for the ZFP42 gene,
cg03975694 for the ZNF540 gene, cg08668790 for the ZNF154 gene,
cg01009664 for the TRH gene, cg22040627 for the SLC13A5 gene, and
cg19246110 for the ZNF671 gene) were examined by the MassArray
platform in the learning cohort. Significant correlations between DNA
methylation levels determined by our previous Infinium assay [7] and
those determined by the present MassArray analysis were confirmed
(P = 1.25 × 10−35, P = 1.98X10−32, P = 1.31 × 10−41, P = 5.30 × 10−34,
P = 7.91 × 10−22 and P = 7.61 × 10−44, respectively).
Additional file 7: Table S5. Differences of DNA methylation levels at all
examined 193 CpG units including 299 CpG sites of 14 CpG island
methylator phenotype (CIMP) marker genes between CIMP-negative and
CIMP-positive clear cell renal cell carcinomas (ccRCCs) in the learning
cohort.
Additional file 8: Table S6 Eighty-six CpG units showing area under
the curve (AUC) values larger than 0.9 in receiver operating characteristic
curve analysis for discrimination of CpG island methylator phenotype
(CIMP)-positive clear cell renal cell carcinomas (ccRCCs) from
CIMP-negative ccRCCs in the learning cohort.
Additional file 9: Figure S3. Kaplan–Meier survival curves of patients
with CIMP-positive and -negative high-grade (grades 3 and 4) and
high-stage (stages III and IV) clear cell renal cell carcinomas (ccRCCs) in
the validation cohort. The cancer-free (Panel A, P = 1.01 × 10−3) and
overall (Panel B, P = 7.04 × 10−4) survival rates of patients with CIMP-positive
grade 3/4 ccRCCs were significantly lower than those of patients with
CIMP-negative grade 3/4 ccRCCs (log-rank test). The cancer-free (Panel C,
P = 7.76 × 10−4) and overall (Panel D, P = 5.48 × 10−5) survival rates of
patients with CIMP-positive stage III/IV ccRCCs were significantly lower than
those of patients with CIMP-negative stage III/V ccRCCs (log-rank test).
Patients who underwent curative resection are included in panels A and C.
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